Clinical trials: MG - Myasthenia Gravis
Refractory Myasthenia Gravis, Rituximab
Efficacy and Safety of Low-dose Rituximab in the Treatment of Refractory Myasthenia Gravis
This study is designed to evaluate the effectiveness and safety of low-dose rituximab in patients with refractory myasthenia gravis.
- Trial name
- NCT05332587
- Testing
- Rituximab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
Myasthenia Gravis, Generalized
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
The purpose of the HARMONY 360 investigation is to explore the feasibility of using MyoSense 360 digital measures to develop models capable of detecting clinically meaningful changes in generalized Myasthenia Gravis (gMG)…
- Trial name
- HARMONY 360 (NCT07323316)
- Testing
- MyoSense 360
- Volunteers
- 100 people
- Sponsor
- Ad scientiam
Refractory Myasthenia Gravis
A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
Myasthenia gravis is a disease that happens because the immune system attacks the nervous system. The damage is caused by antibodies produced by B lymphocytes.
- Trial name
- NCT00619671
- Testing
- Rituximab (Rituxan)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Vermont
Ocular Myasthenia Gravis
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk factors of conversion to generalized MG(GMG).
- Trial name
- TREAT-OMG (NCT04182984)
- Testing
- Symptomatic Treatment, Steroids, Immunosuppressive Agents( azathioprine, tacrolimus, Mycophenolate Mofetil)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tang-Du Hospital
Generalized Myasthenia Gravis
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized Myasthenia Gravis (gMG).
- Trial name
- NIMBLE (NCT05070858)
- Testing
- Pozelimab + Cemdisiran, Cemdisiran, Pozelimab
- Where
- 116 sites in United States, Belgium and 17 more
- Volunteers
- 288 people
- Sponsor
- Regeneron Pharmaceuticals
Myasthenia Gravis, Ocular Myasthenia Gravis
Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis
This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of ptosis secondary to myasthenia gravis.
- Trial name
- NCT05045248
- Testing
- Apraclonidine Hcl 0.5% Oph Soln
- Where
- Lebanon
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- American University of Beirut Medical Center
Myasthenia Gravis
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia Gravis
This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Myasthenia gravis.
- Trial name
- NCT06933563
- Testing
- UCAR T-cell group
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Myasthenia Gravis Exacerbations
A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations
This was a multicenter, prospective, open-label, non-controlled study to assess the efficacy and safety of an IV dose of 2 g/kg of IGIV-C in subjects with MG exacerbations.
- Trial name
- NCT02413580
- Testing
- IGIV-C
- Where
- 31 sites in Argentina, Belgium and 10 more
- Volunteers
- 49 people
- Sponsor
- Grifols Therapeutics LLC
Generalized Myasthenia Gravis (gMG)
An Open-label, Dose-escalation Phase Ib Study of EA5 Injection in Adults With Anti-AChR Antibody-Positive Generalized Myasthenia Gravis
This is a Phase Ib, open-label, dose-escalation, single-center/multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of multiple doses of EA5 (a humanized…
- Trial name
- NCT07818291
- Testing
- EA5
- Where
- 2 sites in China
- Volunteers
- 18 people
- Sponsor
- Shanghai Lanyi Therapeutics Co., Ltd.
Myasthenia Gravis
Oxaloacetate in Myasthenia Gravis
This is a phase 1 clinical trial studying whether or not oxaloacetate has a positive effect on patients with Myasthenia Gravis. Patients will be assigned to one of three cohorts which will determine the dose of oxaloacetate they…
- Trial name
- NCT04965987
- Testing
- Oxaloacetate
- Where
- United States
- Sponsor
- University of Kansas Medical Center
Myasthenia Gravis, Generalized
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
The purpose of this Phase 3 study is to demonstrate the efficacy, safety, and tolerability of claseprubart in participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT07647510
- Testing
- Claseprubart
- Where
- 4 sites in United States
- Volunteers
- 195 people
- Sponsor
- Dianthus Therapeutics
Myasthenia Gravis
Prevalence and Impact of Fatigue in Myasthenic Patients Followed At Clermont-Ferrand University Hospital - "My" Asthenia
After identifying myasthenic patients meeting the inclusion criteria, telephone contact with patients to suggest that they participate in the study by responding to various questionnaires composed of validated scales used in…
- Trial name
- NCT06877403
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Clermont-Ferrand
Myasthenia Gravis, Generalized Myasthenia
Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis
Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.
- Conditions
- Myasthenia Gravis, Generalized Myasthenia, AChR Myasthenia Gravis, MuSK MG
- Trial name
- NCT06106672
- Testing
- CNP-106
- Where
- 17 sites in United States
- Volunteers
- 54 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Myasthenia Gravis
Immune Profiles in Myasthenia Gravis
The investigators aim to better describe the immune profile in myasthenia gravis (MG), including lymphocyte subset, cytokine and complement profiles; how they differ between patients of different severity, at times of disease…
- Trial name
- NCT05095103
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Myasthenia Gravis
Influence of Minimally Invasive Thymectomy on the Subsequent Clinical Course of Myasthenia Gravis
The aim of this study is to investigate whether minimally invasive thymectomy achieves comparable efficacy and safety results compared to open thymectomy in patients with myasthenia gravis.
- Trial name
- NCT04158661
- Testing
- thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy), thymectomy by means of median sternotomy (transsternal), no thymectomy (control)
- Where
- 3 sites in Germany
- Volunteers
- 248 people
- Sponsor
- Charite University, Berlin, Germany
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Myasthenia Gravis, Generalized
Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Efficacy and safety of amifampridine phosphate in improving the activities of daily living for patients with antibody positive MuSK myasthenia gravis.
- Trial name
- NCT03304054
- Testing
- Amifampridine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- Catalyst Pharmaceuticals, Inc.
Myasthenia Gravis
A Study in Patients With Myasthenia Gravis in China
This study is a multi-center, prospective cohort study designed to characterize current clinical practice, clinical and patient-reported outcomes (PROs), disease prognosis, treatment patterns and healthcare resource utilization…
- Trial name
- MG Cohort (NCT06700616)
- Where
- 20 sites in China
- Volunteers
- 1,199 people
- Sponsor
- AstraZeneca
Generalized Myasthenia Gravis
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of inebilizumab administered in pediatric participants with gMG, and to assess the safety and tolerability of…
- Trial name
- THYME (NCT06987539)
- Testing
- Inebilizumab
- Where
- 14 sites in United States, Argentina and 6 more
- Volunteers
- 15 people
- Sponsor
- Amgen
Effectiveness
A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia Gravis
Under conventional treatment regimens, pediatric ocular myasthenia gravis (OMG) is prone to relapse and is associated with corticosteroid-related adverse effects, indicating an unmet clinical need.
- Trial name
- NCT07298928
- Testing
- Telitacicept
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine